Welcome to our dedicated page for Dare Bioscience SEC filings (Ticker: DARE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Daré Bioscience, Inc. (NASDAQ: DARE) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents include current reports on Form 8-K, quarterly and annual reports when available, and exhibits such as press releases and corporate presentations that the company uses to communicate material information about its operations and strategy.
Daré’s recent 8-K filings illustrate several key themes. Some reports furnish earnings press releases and corporate updates, outlining financial results, cash position, research and development spending and the status of programs such as DARE to PLAY Sildenafil Cream, Ovaprene and other pipeline assets. Other 8-Ks describe interim clinical data for Ovaprene’s pivotal Phase 3 study, including data safety monitoring board recommendations and information on pregnancy rates, tolerability and study design.
Additional 8-K filings address corporate and listing matters, such as Nasdaq correspondence regarding compliance with Listing Rule 5550(b) for stockholders’ equity and market value of listed securities, and the company’s multi-step plan to maintain its listing on The Nasdaq Capital Market. There are also filings related to stock incentive plan amendments and stockholder meeting results, which provide detail on governance decisions and equity compensation arrangements.
Through Stock Titan, users can review Daré’s SEC filings in one place and use AI-powered tools to summarize complex documents. These tools can help explain the implications of items such as clinical trial updates, grant agreements, listing notices and capital-raising activities. Investors interested in Daré’s women’s health portfolio, regulatory status and financing strategy can use this page to monitor new 8-Ks and other filings as they are posted to EDGAR, and to quickly interpret how those disclosures relate to the company’s pipeline and commercialization plans.
Daré Bioscience, Inc. files its Form 10-K reporting a strategic shift to a dual-path commercial model that pursues FDA approvals and earlier market access via Section 503B compounding, plus consumer health product launches. The company began commercialization of DARE to PLAY sildenafil cream in December 2025 and expects sales and pharmacy dispensing to begin in Q2 2026. Pipeline priorities include a pivotal Phase 3 study of Ovaprene (monthly, hormone-free contraceptive), planned Phase 3 activity for Sildenafil Cream for FSAD, DARE-HRT1 intravaginal ring for menopause symptoms, and ARPA-H-funded development of DARE-HPV. The company disclosed 14,559,502 shares outstanding as of March 25, 2026 and an aggregate market value of non-affiliate shares of approximately $21,339,826 as of its most recent second fiscal quarter.
Daré Bioscience is asking stockholders to vote at its virtual 2026 annual meeting on June 11, 2026. Holders of 14,559,502 shares of common stock as of April 14, 2026 may attend and vote online.
Key items include electing two Class III directors, ratifying Haskell & White LLP as auditor, and advisory votes on executive pay and how often that say‑on‑pay vote should occur. Stockholders are also asked to approve a potential future issuance of common stock to Lincoln Park Capital Fund, LLC under Nasdaq rules, and to amend the 2022 Stock Incentive Plan to add 1,500,000 shares for equity awards.
The proxy details board composition, governance practices, ownership, and 2025 executive pay. In 2025, CEO Sabrina Martucci Johnson received total compensation of $801,081 and Chief Accounting Officer MarDee Haring‑Layton received $546,858, largely driven by salary and stock option grants.
Daré Bioscience, Inc. furnished an updated corporate presentation on April 22, 2026. The presentation was made available in the Investors section of the company’s website and attached as Exhibit 99.1 to this report.
The information in Item 7.01 and Exhibit 99.1 is provided under Regulation FD and is expressly stated as furnished, not filed, meaning it is not subject to certain Exchange Act liability provisions and is not automatically incorporated into other Securities Act or Exchange Act filings.
Daré Bioscience, Inc. completed a closing of its Regulation A offering, selling 20,000 Investor Units at an offering price of $5.00 per unit. Each Investor Unit consists of one share of Series A Convertible Preferred Stock and two Investor Warrants, each warrant exercisable for one share of common stock, for a total of up to 40,000 common shares underlying the warrants. The units were issued under an offering statement on Form 1-A that was most recently qualified by the SEC on April 1, 2026, together with an offering circular dated January 6, 2026 and an offering circular supplement dated March 26, 2026.
Daré Bioscience, Inc. reported a change in how its board of directors is classified. The six-member board is divided into three classes, with one class elected each year for a three-year term. To rebalance these classes, director Gregory W. Matz voluntarily resigned as a Class II director, whose term would have expired at the 2028 annual meeting, and was simultaneously reappointed as a Class III director, whose term will expire at the 2026 annual meeting. Mr. Matz and Sabrina Martucci Johnson, the other Class III director, will stand for re-election at the 2026 annual meeting of stockholders. The company stated that this step was taken solely to rebalance the three director classes, that Mr. Matz’s service is deemed continuous for all other purposes, and that his board committee assignments did not change.
Daré Bioscience, Inc. is soliciting proxies for its 2026 Annual Meeting of Stockholders to be held virtually on June 11, 2026. Key items for stockholder votes include election of two Class III directors; ratification of Haskell & White LLP as auditor; advisory votes on executive compensation and frequency; Nasdaq-required approval for potential future issuances to Lincoln Park Capital Fund, LLC; and an amendment to increase the 2022 Stock Incentive Plan by 1,500,000 shares. The record date for voting was April 14, 2026, when 14,559,502 shares were outstanding. The proxy materials explain voting methods, quorum and broker voting treatment and note that final results will be filed on Form 8-K.
Daré Bioscience, Inc. completed a closing of its previously announced Regulation A offering of Investor Units. In this closing, the company issued 3,470 Investor Units, each priced at $5.00 and consisting of one share of Series A Convertible Preferred Stock and two Investor Warrants.
The 3,470 Investor Units therefore represent 3,470 shares of Series A Preferred Stock and Investor Warrants to purchase up to 6,940 shares of Daré’s common stock. The offering is being conducted under an offering statement on Form 1-A qualified by the SEC, together with an offering circular and an offering circular supplement.
Daré Bioscience outlines an expanded women’s health strategy in its annual report, combining traditional FDA drug development with Section 503B compounding and consumer health products. The company is beginning to commercialize proprietary formulations while advancing a diversified clinical pipeline.
Near term, Daré plans revenue from DARE to PLAY sildenafil cream, compounded via 503B outsourcing facilities, with dispensing expected in the second quarter of 2026, and from DARE to RESTORE Flora Sync LF5 vaginal probiotic suppositories, also targeted for U.S. launch in the second quarter of 2026. A second compounded product, DARE to estradiol progesterone intravaginal ring, is aimed for early 2027.
The report highlights progress on key clinical programs: Ovaprene, a hormone-free monthly contraceptive in a pivotal Phase 3 study; Sildenafil Cream, 3.6% for female sexual arousal disorder, preparing for Phase 3 after FDA feedback; DARE-HRT1, a bio-identical estradiol/progesterone ring heading toward Phase 3; DARE-HPV, backed by up to $10 million from ARPA-H and cleared for a Phase 2 IND; and additional programs like DARE-VVA1 for dyspareunia. Daré emphasizes partnerships, non-dilutive funding, and outsourced commercial infrastructure to reduce reliance on equity capital.
Daré Bioscience reported full-year 2025 results that highlight a transition toward commercialization while still operating at a loss. Total revenue rose to $1,030,193 from $9,784 in 2024, primarily from license and other revenue, while net loss widened to $13,399,274 versus $4,053,599.
Selling, general and administrative expenses were $8,763,376, slightly below 2024, and research and development expenses fell sharply to $5,523,352 from $14,305,208, helped by $16,400,000 of contra-R&D grant funding. Daré raised approximately $20,800,000 in equity proceeds in 2025 and received about $13,600,000 from the Gates Foundation, $4,500,000 under its ARPA-H award, and $1,300,000 in NIH reimbursements.
As of December 31, 2025, cash and cash equivalents were $24,711,356, total assets were $32,474,563, and stockholders’ equity improved to $2,842,634. The company is preparing multiple near-term catalysts, including the launch of DARE to PLAY sildenafil cream and DARE to RESTORE Flora Sync LF5 in Q2 2026, continued Ovaprene Phase 3 enrollment, and advancing DARE-HPV into Phase 2 with non-dilutive funding.
Daré Bioscience, Inc. completed a closing of its previously announced Regulation A offering of Investor Units. The company issued 43,050 Investor Units at an offering price of $5.00 per unit, each unit consisting of one share of Series A Convertible Preferred Stock and two Investor Warrants.
These 43,050 Investor Units include 43,050 shares of Series A Preferred Stock and Investor Warrants to purchase up to 86,100 shares of Daré’s common stock. The offering is being conducted under an offering statement on Form 1-A qualified by the SEC on January 5, 2026, and an offering circular dated January 6, 2026.